Adam Bonislawski

Premium Save for later NEW YORK – As implementation of the US Food and Drug Administration's (FDA) final rule on laboratory-developed tests (LDTs) continues amidst legal challenges from several industry stakeholders, efforts are also afoot to revive legislative approaches to LDT regulation and diagnostics reform.

NEW YORK – Protein sequencing firm Quantum-Si announced last week plans to develop a platform capable of large-scale proteomics experiments.

NEW YORK – Proteomics firm Nautilus Biotechnology has generated data indicating that its proteomics platform can detect around 800 proteoforms of the Alzheimer's disease-associated protein tau.

NEW YORK – For the proteomics market, 2024 was more a year of incremental progress than dramatic developments as the field continued to incorporate the advances of recent years.

NEW YORK – A team led by researchers at the University of Hong Kong and the Columbia University Mailman School of Public Health have devised a new method for Mendelian randomization experiments tailored to proteomic datasets.

NEW YORK – Backed by $15 million in Series A funding, Taiwanese life science firm Syncell is looking to drive commercialization of its spatial proteomics platform.

NEW YORK – Total private investment in life science tools and diagnostics firms in the second half of 2024 was up nearly 10 percent from a year ago, according to an analysis of deals reported by GenomeWeb

Premium Save for later NEW YORK – For clinical labs, 2024 will most likely be remembered as the year the US Food and Drug Administration finally made good on its decades-old promise — or threat, depending on your point of view — to regulate laboratory-developed tests (LDTs).

Premium Save for later NEW YORK – Diagnostics firm Proteomics International (PIL) plans to launch its proteomic test for endometriosis in Australia in the first half of the year with a US launch to follow shortly thereafter.

Premium Save for later NEW YORK – Following the European launch of its new Cobas i 601 mass spectrometry analyzer in December, Roche is now preparing to release an initial set of tests on the instrument including for steroid hormones, Vitamin D, and immunosuppressant and therapeutic drug monitoring.